| Current Price | $18.53 | Mkt Cap | $3.0B |
|---|---|---|---|
| Open | $19.18 | P/E Ratio | 0.00 |
| Prev. Close | $19.24 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $18.49 - $19.30 | Volume | 1,795,733 |
| 52-Wk Range | $18.49 - $20.63 | Avg. Daily Vol. | 1,494,442 |
A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
| Current Price | $18.53 | Mkt Cap | $3.0B |
|---|---|---|---|
| Open | $19.18 | P/E Ratio | 0.00 |
| Prev. Close | $19.24 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $18.49 - $19.30 | Volume | 1,795,733 |
| 52-Wk Range | $18.49 - $20.63 | Avg. Daily Vol. | 1,494,442 |
The best Bull and Bear pitches based on recency and number of recommendations.
Several meds currrently in the 3rd stage of the pipeline, two on the market with one being a treatment for opiod addiction makes this a solid investment. A bonus is investing in a company whose products can actually save lives.
Almost got the top on this one.
Read the most recent pitches from players about ALKS.
Recs
BlueLens
(48.53)
Submitted: 12/29/2019 1:54:11 PM :
Start Price:
$20.41
NASDAQ:ALKS Score:
-10.24
Long acting injectable medication is preferred by patients for convenience. Preferred by society because adherence to treatment is better with long acting injectables. Lower side effects, like less weight gain, will improve medication adherence. Many system delivery barriers to use of injectable medications, but positive impact on public safety will win the day.
Recs
airenInDebt
(68.38)
Submitted: 8/9/2018 4:18:27 PM :
Start Price:
$44.59
NASDAQ:ALKS Score:
-74.62
Several meds currrently in the 3rd stage of the pipeline, two on the market with one being a treatment for opiod addiction makes this a solid investment. A bonus is investing in a company whose products can actually save lives.
Recs
XMFRendezvous
(92.29)
Submitted: 4/21/2018 1:17:56 AM :
Start Price:
$46.31
NASDAQ:ALKS Score:
-83.27
Alkermers is primarily involved in producing generic versions or "biosimilars" of already marketed name-brand drugs. The Affordable Care Act encourages the use of generic drugs, which are cheaper. R&D costs are lower, but so are the margins. This is a socially responsible business model, and is the the direction the pharmaceutical industry is headed.
Find the members with the highest scoring picks in ALKS.
Gib323 (< 20) Score: +622.96
The Score Leader is the player with the highest score across all their picks in ALKS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| optigon123 | < 20 | 7/20/2009 |
|
3M | $10.57 | +78.33% | +251.62% | +173.29 | 0 Comment | |
| scottidog | 59.52 | 9/29/2010 |
|
5Y | $14.61 | +29.02% | +189.89% | +160.87 | 0 Comment | |
| boardsecurities | 29.19 | 8/2/2013 |
|
5Y | $33.73 | -44.12% | +94.59% | +138.70 | 0 Comment | |
| AnotherOldFart | 34.48 | 10/12/2006 |
|
3M | $15.58 | +20.99% | +159.47% | +138.48 | 0 Comment | |
| dwn88ir | 58.47 | 4/23/2012 |
|
5Y | $17.47 | +7.90% | +142.67% | +134.77 | 0 Comment | |
| cmc1981 | 29.92 | 3/31/2014 |
|
5Y | $43.77 | -56.93% | +77.15% | +134.08 | 0 Comment | |
| cthomas1017 | 98.95 | 8/8/2012 |
|
5Y | $17.73 | +6.32% | +136.50% | +130.19 | 0 Comment | |
| hoochkitty | 32.41 | 8/24/2007 |
|
5Y | $16.79 | +12.27% | +136.56% | +124.29 | 0 Comment | |
| alvinbentley | 29.07 | 6/30/2008 |
|
5Y | $12.55 | +50.20% | +165.96% | +115.76 | 0 Comment | |
| IamBetterThanYou | < 20 | 10/20/2010 |
|
3W | $10.80 | +74.54% | +180.16% | +105.62 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
